Inflarx N.V. (IFRX) has released an update.
InflaRx N.V., a biotech company specializing in anti-inflammatory therapeutics, has emphasized its commitment to pioneering treatments for inflammatory diseases through its proprietary technology targeting the complement activation factor C5a and its receptor C5aR. The company’s leading product, vilobelimab, has shown promising clinical activity in treating diverse indications and is in late-stage development for Pyoderma Gangrenosum (PG). InflaRx boasts a robust balance sheet, projecting financial sustainability into at least 2026 while advancing its clinical programs.
For further insights into IFRX stock, check out TipRanks’ Stock Analysis page.
